All News

generic

All News

Zentiva to further expand its geographical footprint and complement its portfolio in Generics and OTC

11/11/19
PRAGUE / SOFIA, – 25 OCTOBER 2019 – Zentiva announces the signing of a definitive agreement to acquire the Central and Eastern European Business of Alvogen, for an undisclosed amount Alvogen CEE markets over 200 generic and over-the-counter products across multiple therapeutic areas, consisting of highly recognized brands like Lactacyd, Persen, EuBiotic and many more with leading...
Read

Zentiva enhances its global manufacturing footprint by signing an agreement to acquire manufacturing site in Ankleshwar, India

11/09/19
PRAGUE / MUMBAI / ANKLESHWAR – September 11th, 2019: Zentiva Group, a.s. announces the signing of a Business Transfer Agreement with Sanofi to acquire their manufacturing site in Ankleshwar, India. This acquisition will help ensure the continued supply of high-quality medicines to more patients by expanding the footprint and agility of Zentiva’s manufacturing network.“Expanding...
Read

Blackrock Hydroxycholoroquine 200mg tablets availability

28/08/19
Blackrock Hydroxycholoroquine 200mg tablets availability
Patient Access to Blackrock Pharmaceuticals, Hydroxychloroquine Sulfate 200 mg film coated tablets(HCQ); PL33271/0001Please download this PDF provided by Blackrock Pharmaceuticals which provides further details on Hydroxychloroquine 200mg tablets.
Read

Creo Pharma Transfers of Value (ToV) for 2018 to Healthcare Professionals

01/08/19
Creo Pharma Transfers of Value (ToV) for 2018 to Healthcare Professionals
As a member of the BGMA, Creo Pharma are signed up to the Medicines for Europe Code of Conduct. The information below is Creo Pharma’s 'Transfers of Value' disclosure for 2018.The code is inclusive of all Healthcare Professionals who received a transfer of value from Creo Pharma. This disclosure ensures Creo Pharma’s continued compliance with the Medicines for Europe Code of...
Read

Creo Pharma no longer supply Virazole IV

02/06/19
Creo Pharma no longer supply Virazole IV
Creo Pharma no longer supply the Meda/Mylan unlicensed products Virazole IV (Ribavirin). For information regarding the supply of Virazole IV (Ribavirin) please contact Mylan direct on +44 (0) 800 1218 267. If you have any medical related questions and/or are reporting an adverse event on any Mylan  products please call +44 (0) 800 1218 267, then chose Option 1 for the Medical Information...
Read

Creo Pharma are Cyber Essentials accredited

10/04/19
Creo Pharma are Cyber Essentials accredited
Launched by the UK Government in 2014, the Cyber Essentials Scheme looks to improve organisations technical controls against online threats. As of 12th February 2019, Creo Pharma were confirmed as Cyber Essentials accredited, meaning that our IT systems are suitably secure against common online threats. This certification ensures Creo Pharma continue to take online security seriously, for...
Read

Zentiva announces the acquisition of Creo Pharmaceuticals Ltd. in the UK

03/04/19
Zentiva announces the acquisition of Creo Pharmaceuticals Ltd. in the UK
PRAGUE – April 1st, 2019: Zentiva Group a.s. is announcing the acquisition of Creo Pharmaceuticals Ltd. in the UK, a subsidiary of Amneal Pharmaceuticals, Inc. (NYSE: AMRX).Nick Haggar, CEO of Zentiva stated: “Zentiva is delighted to confirm the acquisition of Creo Pharma which will strengthen Zentiva’s position in the UK. This move reflects our confidence in the UK and...
Read

Creo Pharma - GDPR statement

27/06/18
Creo Pharma - GDPR statement
The new General Data Protection Regulation (GDPR) became effective from 25th May 2018. We at Creo Pharma will continue to respect the security and sensitivity of information shared with us. We have updated our Privacy policy to reflect the changes in Regulation, and to provide further information on how we collect, store and use your personal data.You can read our full updated policy on our Terms...
Read

Creo Pharma Transfers of Value (ToV) for 2017 to Healthcare Professionals

26/06/18
Creo Pharma Transfers of Value (ToV) for 2017 to Healthcare Professionals
As a member of the BGMA, Creo Pharma are signed up to the Medicines for Europe Code of Conduct. The information below is Creo Pharma’s 'Transfers of Value' disclosure for 2017.The code is inclusive of all Healthcare Professionals who received a transfer of value from Creo Pharma. This disclosure ensures Creo Pharma’s continued compliance with the Medicines for Europe Code of...
Read

Trazodone 100mg/5ml oral solution sugar-free (120ml)

26/01/18
Trazodone 100mg/5ml oral solution sugar-free (120ml)
We are delighted to announce that in February, Creo Pharma was the first supplier able to offer a licensed Trazodone 100mg/5ml oral solution sugar-free (120ml). For more information, please view the Creo Pharma Database Listing for this product.
Read

Ranitidine 150mg/5ml oral solution sugar-free (150ml)

18/01/18
Ranitidine 150mg/5ml oral solution sugar-free (150ml)
We are delighted to announce that in November, Creo Pharma was the first supplier able to offer a licensed Ranitidine 150mg/5ml oral solution sugar-free (150ml). For more information, please view the Creo Pharma Database Listing for this product.
Read

Alendronic Acid and Colecalciferol tablets

30/08/17
Alendronic Acid and Colecalciferol tablets
On 30th August 2017, Creo Pharma dispatched launch orders for its generic Alendronic acid 70 mg and Colecalciferol 2800IU tablets to customers. For more information, please view the Creo Pharma Database Listing for this product.
Read